Once-weekly Lilly diabetes drug wins EU approval

November 25, 2014 6:53 PM

12 0

(Reuters) - The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.

The once-weekly drug belongs to a family of diabetes treatments called GLP-1 receptor agonists, which includes Novo Nordisk's widely used daily treatment Victoza. They act like GLP-1, a natural hormone, in prodding the body to release insulin when patients eat.

Read more

To category page